info@RegenProtocols.com
561-325-7000
141 NW 20th St., Suite G1 Boca Raton, FL 33431
A two-phase neuro-restorative approach to age-related cognitive decline and executive dysfunction that pairs peptides with cognitive behavioral therapy.
Critical safety note on managing BDNF and excitotoxicity: this protocol strongly upregulates brain-derived neurotrophic factor (BDNF). While therapeutic for repair, excessive BDNF can lead to hyperexcitability, so physicians must monitor for the risks listed below. This protocol is contraindicated in patients with epilepsy.
A neuro-restorative, biphasic approach to age-related cognitive decline (ARCD), executive dysfunction such as ADHD, and early-stage neurodegenerative disease such as Alzheimer's disease, Lewy body dementia, and symptoms of Parkinson's disease. Unlike traditional stimulant therapies, which only mask symptoms temporarily, this regimen uses two phases to rebuild neural and synaptic systems while cognitive behavioral therapy (CBT) solidifies the new neuronal patterns.
Phase 1 focuses on aggressive synaptogenesis, mitochondrial restoration, and dendritic branching to physically rebuild neural architecture. Start the appropriate CBT protocol before Phase 1 begins, so the patient has the tools to apply what they learn while new neuronal and synaptic systems form. The specifics of the CBT protocol are outside the scope of this article. The focus should be on reinforcing the tools gained through CBT in a safe environment that does not discourage the patient when mistakes happen.
Phase 2 uses this heightened neuroplasticity to solidify behavioral patterns through CBT. Tailor the CBT protocol to the patient's needs, lifestyle, and stage of disease. The specifics are again outside the scope of this article. Each session in this phase should prioritize affirming what the patient has learned so far. NA-Semax-Amidate and NA-Selank-Amidate are added to take advantage of a window of enhanced neuroplasticity and resilience during CBT sessions.
Strict adherence to dosing windows is required to balance brain-derived neurotrophic factor (BDNF) elevation against inhibitory control. Otherwise, patients may experience excitotoxicity, which severely limits functional gains and long-term potentiation. If a patient has anxiety and/or excitotoxicity effects during Phase 1, anxiolytics and/or an extra dose of L-theanine can be added to relieve them. With a proper low-to-moderate fat diet and adherence to the protocol, these effects should be fully mitigated.
This protocol is indicated for patients with subjective age-related cognitive decline (ARCD), early-stage memory impairment, or executive dysfunction such as ADHD (inattentive type). Ideal candidates are motivated to take part in active cognitive behavioral therapy (CBT) alongside pharmacological treatment.
Screen patients for a history of seizures, active malignancy (because of the angiogenic properties of Dihexa), and mania (because the excitatory nature of the stack could worsen bipolar disease).
| Agent | Route | Dose |
|---|---|---|
| Dihexa | Oral | 5 mg |
| P21 | Subcutaneous or intranasal | 600 mcg subcutaneous; 1,000 mcg intranasal |
| J-147 | Oral | 15 mg |
| Noopept | Oral | 30 mg |
An angiotensin IV analog with strong neurogenic activity. It stimulates dendritic branching and synaptogenesis through the HGF/c-Met pathway, which increases the available neurons and synaptic pathways.
A synthetic mimetic of ciliary neurotrophic factor (CNTF) that directs neural stem cells to mature into functional neurons rather than glial scar tissue. It works with Dihexa to densify the neural network.
A curcumin derivative developed to treat the aging brain. It targets mitochondrial ATP synthase to restore cellular energy production and reduces neuroinflammation, which supplies the metabolic energy that the rapid neuronal growth triggered by Dihexa and P21 requires.
A peptide mimetic that improves signal-to-noise ratio and sensory gating through acetylcholine and AMPA receptor sensitization. This gives an immediate improvement in focus while supporting NGF and BDNF expression.
| Agent | Route | Dose |
|---|---|---|
| NA-Semax-Amidate | Intranasal or subcutaneous | 750 mcg intranasal; 300 mcg subcutaneous |
| NA-Selank-Amidate | Intranasal or subcutaneous | 750 mcg intranasal; 300 mcg subcutaneous |
An ACTH fragment that rapidly raises BDNF and modulates the dopaminergic system. Used just before CBT, it creates a "plasticity window" that improves retention of new coping strategies and organizational skills.
An anxiolytic peptide that modulates GABA and inhibits enkephalin degradation. It reduces the stress response that often comes with cognitive effort or therapy and supports a state of "relaxed focus."
| Agent | Route | Dose | Frequency |
|---|---|---|---|
| Alpha-GPC | Oral | 300 mg | Daily (morning in Phase 1) |
| Magnesium L-threonate | Oral | 500 mg | Daily, 2 hours before bed |
| L-theanine | Oral | 200 mg | Daily, 2 hours before bed |
A fast-acting choline donor that supplies the acetylcholine precursor needed to sustain the high-speed signaling induced by Noopept and Semax, and prevents headaches from cholinergic depletion.
The only form of magnesium shown to raise brain magnesium levels. This helps prevent excitotoxicity during synaptogenesis, which can follow the upregulation of NMDA receptors.
An amino acid that promotes alpha-wave production and, when paired with magnesium L-threonate, helps regulate excitatory signaling.
Why: The structural agents are strictly limited to a 4-week cycle. This leaves a washout period in which the brain stabilizes the new connections without desensitizing the receptors.
The excitatory nature of Dihexa and Noopept can theoretically lower the seizure threshold.
Mitigation: Magnesium L-threonate is mandatory in this protocol to gate NMDA receptors and dampen unregulated firing. This protocol is contraindicated in patients with epilepsy.
High BDNF levels facilitate long-term potentiation (LTP) of all memories, including traumatic ones. If a patient experiences acute trauma while on this stack, there is a risk of cementing the fear response.
Mitigation: Pairing Phase 2 with CBT directs the neuroplasticity toward positive behavioral restructuring rather than anxiety loops. NA-Selank is included to buffer the stress response.
Continuous stimulation of TrkB and HGF receptors will lead to rapid tolerance and diminishing returns (the "burnout" effect).
Mitigation: The structural agents (Dihexa, P21, J-147, and Noopept) are strictly limited to a 4-week cycle.
